• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

To­bi­ra chair­man’s din­ner with Brent: In­dus­try chat led to a 3-month pur­suit and a stun­ning $1.7B deal

9 years ago
Deals

So­ri­ot’s $3.5B Bril­in­ta dream is dashed by yet an­oth­er big tri­al flop for As­traZeneca

9 years ago
R&D

Sum­mit shares rock­et up, fu­eled by an $842M pact with Duchenne leader Sarep­ta

9 years ago
R&D

Ko­re­an of­fi­cials launch Han­mi probe in wake of tox re­ports; Prothena CEO Schenk dies

9 years ago
News Briefing

Sun Phar­ma takes aim at a crowd­ed mar­ket with an­oth­er IL-23 pso­ri­a­sis drug from Mer­ck

9 years ago
R&D

Mer­ri­mack CEO is out as the biotech re­struc­tures, chop­ping its work­force and over­haul­ing R&D

9 years ago
R&D
Pharma

$95M mega-round in hand, Elaine Sul­li­van sets out to build a Eu­ro­pean on­col­o­gy play­er

9 years ago
R&D

As­traZeneca hands off an­oth­er Am­gen-part­nered drug in a $1.5B deal with an ac­quis­i­tive Al­ler­gan

9 years ago
R&D
Pharma

Presto! Wall Street ma­gi­cian Vivek Ra­maswamy has an­oth­er in­stant biotech IPO to sell you

9 years ago
People
Financing

J&J’s IL-23 star guselkum­ab grabs the spot­light in PhI­II pso­ri­a­sis show­down

9 years ago
R&D

Block­buster per­for­mance: Re­gen­eron, Sanofi add stel­lar PhI­II dupilum­ab da­ta on dis­play at EADV

9 years ago
R&D

Fol­low­ing lethal tox re­port, Boehringer scraps plans for high-speed de­vel­op­ment, kills $730M Han­mi deal

9 years ago
R&D

Thresh­old blast­ed, re­struc­tures af­ter a PhII fail­ure; SQZ rais­es $16M

9 years ago
News Briefing

Week in re­view: Clin­ton over Trump; the hubs have it; we'll al­ways have Paris

9 years ago
Bioregnum
Opinion

Scoop: Cel­gene tar­gets a cure for myelo­ma/lym­phoma with $600M En­gMab buy­out

9 years ago
Deals

In a set­back, Re­gen­eron re­ports a mid-stage flop for next-gen Eylea com­bo

9 years ago
R&D

Im­muno­Gen's new CEO re­trench­es, ax­ing 65 staffers and look­ing to thin pipeline

9 years ago
R&D
Pharma

UCSF sci­en­tist rolls out a new blue­print for pro­gram­ming T cells, the 2.0 way

9 years ago
Startups

Cataba­sis shares rock­et up on Duchenne pact with Sarep­ta; blue­bird whis­tles up a TCR deal with Medi­gene

9 years ago
News Briefing

Am­gen beefs up car­dio pipeline, adding a $673M RNAi deal with Ar­row­head

9 years ago
R&D

Step two: Cel­gene grabs a $20M op­tion, plots MS PhII for Abide’s cannabi­noid drug

9 years ago
R&D

No­vo Nordisk takes out the ax and aims at R&D, chop­ping 1,000 jobs

9 years ago
R&D
Pharma

Genen­tech snares a PhI RAF in­hibitor from Han­mi in $910M deal

9 years ago
R&D
Pharma

FDA slaps a full clin­i­cal hold on Al­co­bra’s trou­bled lead drug for AD­HD, Frag­ile X

9 years ago
R&D
First page Previous page 1161116211631164116511661167 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Confirm Profile

Endpoints News